BRPI0520579B8 - composto, processo para a preparação de um composto e composição farmacêutica - Google Patents

composto, processo para a preparação de um composto e composição farmacêutica

Info

Publication number
BRPI0520579B8
BRPI0520579B8 BRPI0520579A BRPI0520579A BRPI0520579B8 BR PI0520579 B8 BRPI0520579 B8 BR PI0520579B8 BR PI0520579 A BRPI0520579 A BR PI0520579A BR PI0520579 A BRPI0520579 A BR PI0520579A BR PI0520579 B8 BRPI0520579 B8 BR PI0520579B8
Authority
BR
Brazil
Prior art keywords
compound
preparing
pharmaceutical composition
receptor
present
Prior art date
Application number
BRPI0520579A
Other languages
English (en)
Inventor
Vishwottam Kandikere Nagaraj
Sastri Kambhampati Rama
Vishwakarma Santosh
Kota Srinivasulu
Satya Nirogi Ramakrishna Venkata
Jasti Venkateswarlu
Shreekrishna Shirsath Vikas
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of BRPI0520579A2 publication Critical patent/BRPI0520579A2/pt
Publication of BRPI0520579B1 publication Critical patent/BRPI0520579B1/pt
Publication of BRPI0520579B8 publication Critical patent/BRPI0520579B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

composto, processo para a preparação de um composto, método para o tratamento de uma desordem do sistema nervoso central relacionada a ou afetada pelo receptor 5-ht6, composição farmacêutica, uso do composto e método para testar antagonistas e antagonistas com eletividade para o receptor 5-ht6. a presente invenção proporciona derivados de aminoaril sulfonamida de fórmula (i), úteis no tratamento de uma desordem do snc relacionada a ou afetada pelo receptor 5-ht6, o perfil farmacológico los referidos compostos incluem alta afinidade de ligação com o receptor 5-ht6 aliada a uma boa seletividade em relação ao referido receptor. a presente invenção inclui também os estereoisômeros, os sais, os métodos de preparação e um medicamento contendo os referidos derivados de aminoaril sulfonamida.
BRPI0520579A 2005-08-12 2005-10-26 composto, processo para a preparação de um composto e composição farmacêutica BRPI0520579B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1127CH2005 2005-08-12
IN1127/CHE/2005 2005-08-12
PCT/IN2005/000345 WO2007020652A1 (en) 2005-08-12 2005-10-26 Aminoaryl sulphonamide derivatives as functional 5-ht6 ligands.

Publications (3)

Publication Number Publication Date
BRPI0520579A2 BRPI0520579A2 (pt) 2009-11-10
BRPI0520579B1 BRPI0520579B1 (pt) 2019-08-06
BRPI0520579B8 true BRPI0520579B8 (pt) 2021-05-25

Family

ID=36130030

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0520579A BRPI0520579B8 (pt) 2005-08-12 2005-10-26 composto, processo para a preparação de um composto e composição farmacêutica

Country Status (23)

Country Link
US (1) US7998981B2 (pt)
EP (1) EP1919896B1 (pt)
JP (1) JP5091138B2 (pt)
KR (1) KR101016972B1 (pt)
CN (1) CN101258144B (pt)
AT (1) ATE452885T1 (pt)
AU (1) AU2005335620B2 (pt)
BR (1) BRPI0520579B8 (pt)
CA (1) CA2618636C (pt)
CY (1) CY1110276T1 (pt)
DE (1) DE602005018554D1 (pt)
DK (1) DK1919896T3 (pt)
EA (1) EA013875B1 (pt)
ES (1) ES2337167T3 (pt)
HK (1) HK1116796A1 (pt)
MX (1) MX2008002018A (pt)
NO (1) NO340511B1 (pt)
NZ (1) NZ566495A (pt)
PL (1) PL1919896T3 (pt)
PT (1) PT1919896E (pt)
SI (1) SI1919896T1 (pt)
WO (1) WO2007020652A1 (pt)
ZA (1) ZA200801276B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0718737A2 (pt) 2007-01-08 2014-03-25 Suven Life Sciences Ltd "composto, processo para a preparação de um composto, método para o tratamento de uma desordem do sistema nervoso central, composição farmacêutica, uso do composto, método para testar antagonistas e antagonistas com seletividade para o receptor 5-ht6, e método de tratamento"
WO2008136017A1 (en) * 2007-05-03 2008-11-13 Suven Life Sciences Limited Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands
NZ585374A (en) 2007-10-26 2011-09-30 Suven Life Sciences Ltd Amino arylsulfonamide compounds for treating disorders related to 5-HT6 receptor functions
WO2010032257A1 (en) * 2008-09-17 2010-03-25 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands
ES2552463T3 (es) * 2010-01-05 2015-11-30 Suven Life Sciences Limited Compuestos aromáticos de sulfona útiles para el tratamiento de enfermedades del sistema nervioso central
CN102153884B (zh) * 2011-02-16 2013-06-19 连云港清泰化工有限公司 一种墨水型染料及其制备方法与用途
JP6454346B2 (ja) 2013-12-20 2019-01-16 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 芳香族複素環式化合物及び医薬におけるその応用
SG11201610407QA (en) 2014-07-08 2017-01-27 Sunshine Lake Pharma Co Ltd Aromatic heterocyclic derivatives and pharmaceutical applications thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69230803T2 (de) * 1991-11-25 2000-12-07 Pfizer 5-(hetero- oder carbocyclylamino)-indol derivate, deren herstellung und deren verwendung als 5-ht1 agonisten
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
TR200000073T2 (tr) 1997-07-11 2000-06-21 Smithkline Beecham P.L.C. 5-HT6 Reseptör antagonistleri olan sülfonamid türevleri ve bunların hazırlanma prosesi
GB9801392D0 (en) 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
GB9803411D0 (en) 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
GB9926302D0 (en) 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
ES2264994T3 (es) * 2000-12-22 2007-02-01 Wyeth Compuestos heterociclilalquilindol o -azaindol como ligandos de 5-hidroxitriptamina-6.
KR100863622B1 (ko) 2001-02-08 2008-10-15 메모리 파마슈티칼스 코포레이션 포스포디에스테라제 4 억제제로서의 트리플루오로메틸푸린
CA2452743A1 (en) * 2001-08-03 2003-02-13 Pharmacia & Upjohn Company 5-arylsulfonyl indoles having 5-ht6 receptor affinity
WO2003065046A2 (en) 2002-02-01 2003-08-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
EP1471912A1 (en) 2002-02-05 2004-11-03 Glaxo Group Limited Method of promoting neuronal growth
JP4467307B2 (ja) * 2002-02-22 2010-05-26 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ５−ｈｔ受容体アンタゴニストとしてのピリジルスルホン誘導体
KR100657056B1 (ko) * 2002-06-05 2006-12-13 에프. 호프만-라 로슈 아게 중추 신경계 장애의 치료를 위한 5-ｈｔ6-수용체조절제로서 1-설폰일-4-아미노알콕시 인돌 유도체
DE60309498T2 (de) 2002-10-18 2007-08-30 F. Hoffmann-La Roche Ag 4-piperazinylbenzolsulfonyl-indole mit 5-ht6 rezeptor-affinität
WO2004048331A1 (en) 2002-11-28 2004-06-10 Suven Life Sciences Limited N-arylalkyl-3-aminoalkoxyindoles and their use as 5-ht ligands
NZ540842A (en) 2002-11-28 2008-05-30 Suven Life Sciences Ltd N-arylsulfonyl-3-aminoalkoxyindoles
SI1581492T1 (sl) 2002-11-28 2008-12-31 Suven Life Sciences Ltd N-arilsulfonil-3-substituirani indoli, ki imajo afiniteto za serotoninski receptor, postopek za njihovo pripravo in farmacevtski sestavek, ki jih vsebuje
EP1581538B1 (en) 2002-12-18 2007-02-28 Suven Life Sciences Limited Tetracyclic 3-substituted indoles having serotonin receptor affinity
CA2534312A1 (en) * 2003-09-12 2005-03-24 Applied Research Systems Ars Holding N.V. Sulfonamide derivatives for the treatment of diabetes

Also Published As

Publication number Publication date
NO20080705L (no) 2008-05-06
EA200800573A1 (ru) 2008-08-29
ES2337167T3 (es) 2010-04-21
DE602005018554D1 (de) 2010-02-04
BRPI0520579B1 (pt) 2019-08-06
EP1919896A1 (en) 2008-05-14
NO340511B1 (no) 2017-05-02
CN101258144A (zh) 2008-09-03
US7998981B2 (en) 2011-08-16
BRPI0520579A2 (pt) 2009-11-10
EA013875B1 (ru) 2010-08-30
NZ566495A (en) 2010-06-25
MX2008002018A (es) 2008-03-27
CA2618636A1 (en) 2007-02-22
WO2007020652A1 (en) 2007-02-22
JP5091138B2 (ja) 2012-12-05
HK1116796A1 (en) 2009-01-02
DK1919896T3 (da) 2010-04-19
CA2618636C (en) 2011-01-18
US20100168168A1 (en) 2010-07-01
PL1919896T3 (pl) 2010-05-31
PT1919896E (pt) 2010-02-26
KR20080039984A (ko) 2008-05-07
AU2005335620B2 (en) 2009-12-10
KR101016972B1 (ko) 2011-02-25
ATE452885T1 (de) 2010-01-15
ZA200801276B (en) 2009-02-25
CY1110276T1 (el) 2015-01-14
EP1919896B1 (en) 2009-12-23
SI1919896T1 (sl) 2010-04-30
AU2005335620A1 (en) 2007-02-22
JP2009504633A (ja) 2009-02-05
CN101258144B (zh) 2012-05-30

Similar Documents

Publication Publication Date Title
BRPI0520579B8 (pt) composto, processo para a preparação de um composto e composição farmacêutica
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
BRPI0518459A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar o composto ou um sal farmaceuticamente aceitÁvel do mesmo
MX2009003958A (es) Nuevos derivados de 1,4-benzotiepina-1,1-dioxido sustituidos con radicales bencilo, metodo para su preparacion, productos farmaceuticos que comprenden estos compuestos y su uso.
DOP2009000133A (es) Derivados de indol como agonistas de los receptores s1p1
BRPI0607796A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
BRPI0607309A2 (pt) processos para a preparação de fenilpirazol uréias substituìdas
MX2008002805A (es) Derivados de carboxamida como antagonistas del receptor muscarinico.
TW200740814A (en) Compounds
NO20085257L (no) Purinonderivater som HM74a-agonister
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
MX2009000169A (es) Derivados de purinona como agonistas de hm74a.
DE602006018713D1 (de) Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
ECSP088326A (es) Derivados de benzotiazol ciclobutil amina y su uso como ligandos de los receptores 3 de histamina
BRPI0606639A2 (pt) novo processo para a preparação de indóis substituìdos
EA200870606A1 (ru) Серосодержащие производные пиразола в качестве избирательных антагонистов рецептора каннабиноидов св
BRPI0821611A8 (pt) Derivado de 3-carboxipropil-aminotetralina e compostos relacionados como antagonistas do receptor opióide mu
BRPI0414643A (pt) composto, composições farmacêuticas, e, uso de um composto
BRPI0809873A2 (pt) "composto, processo para a preparação do composto, método para o tratamento de uma desordem do sistema nervoso central, composição farmacêutica, uso do composto, método para testar antagonistas e antagonistas com seletividade para o receptor 5-th6 e método de tratamento"
BRPI0414494A (pt) compostos, composições farmacêuticas, e, uso de um composto
CY1111560T1 (el) Παραγωγα καρβαζολιου ως λειτουργικα συμπλοκα 5-ητ6
BRPI0620694A2 (pt) composto, composição farmacêutica, processo para a preparação do composto, método para o tratamento de doenças inflamatórias mediado pela ativação de p38 map quinase e uso do composto
UA89846C2 (ru) Производные карбоксамида как антагонисты мускариновых рецепторов

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA; OU SEGUNDO O PARECER DA PROCURADORIA NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2162 DE 12/06/2012.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/10/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2641 DE 17-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.